Safety, Pharmacokinetics and Pharmacodynamics of Remogliflozin Etabonate, a Novel SGLT2 Inhibitor, and Metformin When Co-Administered in Subjects With Type 2 Diabetes Mellitus
BMC pharmacology & toxicology - United Kingdom
doi 10.1186/2050-6511-14-25
Full Text
Open PDFAbstract
Available in full text
Date
April 30, 2013
Authors
Publisher
Springer Science and Business Media LLC